High-resolution analysis of HLA class I alterations in colorectal cancer

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Dierssen, Jan Willem F ^a   de Miranda, Noel F C C ^a   Mulder, Arend ^a   van Puijenbroek, Marjo ^a   Verduyn, Willem ^a   Claas, Frans H J ^a   van de Velde, Cornelis J H ^a   Fleuren, Gert Jan ^a   Cornelisse, Cees J ^a   Corver, Willem E ^a   Morreau, Hans ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; DNA; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY;

ALLELE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL ISOLATION; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; DISEASE ACTIVITY; DNA EXTRACTION; FLOW CYTOMETRY; GENOTYPE; HUMAN; HUMAN CELL; MOLECULAR RECOGNITION; PHENOTYPE; POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR ESCAPE; TUMOR LOCALIZATION;

AGED; COLORECTAL NEOPLASMS; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; PHENOTYPE; PLOIDIES;

EID: 33750002697     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-233     Document Type: Article

References (43)

1. Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van Den Eynde BJ, Brasseur F, Boon T: Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002, 188:51-64.
2. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M: Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993, 363:558-561.
3. Thibodeau SN, Bren G, Schaid D: Microsatellite instability in cancer of the proximal colon. Science 1993, 260:816-819.
4. Linnebacher M, Gebert J, Rudy W, Woerner S, Yuan YP, Bork P, von Knebel DM: Frameshift peptide-derived T-cell epitopes: a source of novel tumor- specific antigens. Int J Cancer 2001, 93:6-11.
5. Ishikawa T, Fujita T, Suzuki Y, Okabe S, Yuasa Y, Iwai T, Kawakami Y: Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability. Cancer Res 2003, 63:5564-5572.
6. Saeterdal I, Bjorheim J, Lislerud K, Gjertsen MK, Bukholm IK, Olsen OC, Nesland JM, Eriksen JA, Moller M, Lindblom A, Gaudernack G: Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A 2001, 98:13255-13260.
7. Townsend A, Bodmer H: Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 1989, 7:601-624.
8. Kaklamanis L, Gatter KC, Hill AB, Mortensen N, Harris AL, Krausa P, McMichael A, Bodmer JG, Bodmer WF: Loss of HLA class-I alleles, heavy chains and beta 2-microglobulin in colorectal cancer. Int J Cancer 1992, 51:379-385.
9. Cabrera T, Collado A, Fernandez MA, Ferron A, Sancho J, Ruiz-Cabello F, Garrido F: High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. Tissue Antigens 1998, 52:114-123.
10. Momburg F, Ziegler A, Harpprecht J, Moller P, Moldenhauer G, Hammerling GJ: Selective loss of HLA-A or HLA-B antigen expression in colon carcinoma. J Immunol 1989, 142:352-358.
11. Leong AS: Pitfalls in diagnostic immunohistology. Adv Anat Pathol 2004, 11:86-93.
12. Ljunggren HG, Karre K: Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med 1985, 162:1745-1759.
13. Long EO: Tumor cell recognition by natural killer cells. Semin Cancer Biol 2002, 12:57-61.
14. Oudshoorn M, Doxiadis II, PM BL, Voorter CE, Verduyn W, Claas FH: Functional versus structural matching: can the CTLp test be replaced by HLA allele typing? Hum Immunol 2002, 63:176-184.
15. Mulder A, Kardol M, Regan J, Buelow R, Claas F: Reactivity of twenty-two cytotoxic human monoclonal HLA antibodies towards soluble HLA class I in an enzyme-linked immunosorbent assay (PRA-STAT). Hum Immunol 1997, 56:106-113.
16. Demanet C, Mulder A, Deneys V, Worsham MJ, Maes P, Claas FH, Ferrone S: Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? Blood 2004, 103:3122-3130.
17. Koopman LA, Mulder A, Corver WE, Anholts JD, Giphart MJ, Claas FH, Fleuren GJ: HLA class I phenotype and genotype alterations in cervical carcinomas and derivative cell lines. Tissue Antigens 1998, 51:623-636.
18. Mulder A, Kardol M, Blom J, Jolley WB, Melief CJ, Bruning H: A human monoclonal antibody, produced following in vitro immunization, recognizing an epitope shared by HLA-A2 subtypes and HLA-A28. Tissue Antigens 1993, 42:27-34.
19. Mulder A, Kardol M, Blom J, Jolley WB, Melief CJ, Bruning JW: Characterization of two human monoclonal antibodies reactive with HLA-B12 and HLA-B60, respectively, raised by in vitro secondary immunization of peripheral blood lymphocytes. Hum Immunol 1993, 36:186-192.
20. Corver WE, Koopman LA, Mulder A, Cornelisse CJ, Fleuren GJ: Distinction between HLA class I-positive and -negative cervical tumor subpopulations by multiparameter DNA flow cytometry. Cytometry 2000, 41:73-80.
21. Stam NJ, Vroom TM, Peters PJ, Pastoors EB, Ploegh HL: HLA-A- and HLA-B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. Int Immunol 1990, 2:113-125.
22. Stam NJ, Spits H, Ploegh HL: Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 1986, 137:2299-2306.
23. de Leeuw WJ, van Puijenbroek M, Merx R, Wijnen JT, Brocker-Vriends AH, Tops C, Vasen H, Cornelisse CJ, Morreau H: Bias in detection of instability of the (C)8 mononucleotide repeat of MSH6 in tumours from HNPCC patients. Oncogene 2001, 20:6241-6244.
24. Kloor M, Becker C, Benner A, Woerner SM, Gebert J, Ferrone S, Doeberitz MV: Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Research 2005, 65:6418-6424.
25. de Leeuw WJ, Dierssen J, Vasen HF, Wijnen JT, Kenter GG, Meijers-Heijboer H, Brocker-Vriends A, Stormorken A, Moller P, Menko F, Cornelisse CJ, Morreau H: Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients. J Pathol 2000, 192:328-335.
26. Jass JR, Whitehall VL, Young J, Leggett BA: Emerging concepts in colorectal neoplasia. Gastroenterology 2002, 123:862-876.
27. Menon AG, Morreau H, Tollenaar RA, Alphenaar E, van Puijenbroek M, Putter H, Janssen-Van Rhijn CM, Van De Velde CJ, Fleuren GJ, Kuppen PJ: Down-regulation of HLA-A expression correlates with a better prognosis in colorectal cancer patients. Lab Invest 2002, 82:1725-1733.
28. Giorda E, Sibilio L, Martayan A, Moretti S, Venturo I, Mottolese M, Ferrara GB, Cappellacci S, Eibenschutz L, Catricala C, Grammatico P, Giacomini P: The antigen processing machinery of class I human leukocyte antigens: linked patterns of gene expression in neoplastic cells. Cancer Res 2003, 63:4119-4127.
29. van den Eisen PJ, Holling TM, Kuipers HF, van der Stoep N: Transcriptional regulation of antigen presentation. Curr Opin Immunol 2004, 16:67-75.
30. Braud VM, Allan DS, McMichael AJ: Functions of nonclassical MHC and non-MHC-encoded class I molecules. Curr Opin Immunol 1999, 11:100-108.
31. Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, Strominger JL, Baltimore D: The selective downregulation of class I major histocompatibility complex proteins by HIV-I protects HIV-infected cells from NK cells. Immunity 1999, 10:661-671.
32. Bicknell DC, Rowan A, Bodmer WF: Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors. Proc Natl Acad Sci U S A 1994, 91:4751-4756.
33. Browning M, Petronzelli F, Bicknell D, Krausa P, Rowan A, Tonks S, Murray N, Bodmer J, Bodmer W: Mechanisms of loss of HLA class I expression on colorectal tumor cells. Tissue Antigens 1996, 47:364-371.
34. Bicknell DC, Kaklamanis L, Hampson R, Bodmer WF, Karran P: Selection for beta 2-microglobulin mutation in mismatch repair-defective colorectal carcinomas. Curr Biol 1996, 6:1695-1697.
35. Cabrera CM, Jimenez P, Cabrera T, Esparza C, Ruiz-Cabello F, Garrido F: Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens 2003, 61:211-219.
36. Lothe RA, Peltomaki P, Meling GI, Aaltonen LA, Nystrom-Lahti M, Pylkkanen L, Heimdal K, Andersen TI, Moller P, Rognum TO: Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 1993, 53:5849-5852.
37. Wright CM, Dent OF, Barker M, Newland RC, Chapuis PH, Bokey EL, Young JP, Leggett BA, Jass JR, Macdonald GA: Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg 2000, 87:1197-1202.
38. Dolcetti R, Viel A, Doglioni C, Russo A, Guidoboni M, Capozzi E, Vecchiato N, Macri E, Fornasarig M, Boiocchi M: High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol 1999, 154:1805-1813.
39. Jass JR, Do KA, Simms LA, Iino H, Wynter C, Pillay SP, Searle J, Radford-Smith G, Young J, Leggett B: Morphology of sporadic colorectal cancer with DNA replication errors. Gut 1998, 42:673-679.
40. Michael-Robinson JM, Biemer-Huttmann A, Purdie DM, Walsh MD, Simms LA, Biden KG, Young JP, Leggett BA, Jass JR, Radford-Smith GL: Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status. Gut 2001, 48:360-366.
41. Young J, Simms LA, Biden KG, Wynter C, Whitehall V, Karamatic R, George J, Goldblatt J, Walpole I, Robin SA, Borten MM, Stitz R, Searle J, McKeone D, Fraser L, Purdie DR, Podger K, Price R, Buttenshaw R, Walsh MD, Barker M, Leggett BA, Jass JR: Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am J Pathol 2001, 159:2107-2116.
42. Menon AG, Janssen-Van Rhijn CM, Morreau H, Putter H, Tollenaar RA, Van De Velde CJ, Fleuren GJ, Kuppen PJ: Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest 2004, 84:493-501.
43. Gunderson LL, Sosin H: Areas of failure found at reoperation (second or symptomatic look) following "curative surgery" for adenocarcinoma of the rectum. Clinicopathologic correlation and implications for adjuvant therapy. Cancer 1974, 34:1278-1292.